The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Lipantil Supra 215 mg, film-coated tablet

Mylan IRE Healthcare LimitedPA2010/015/004

Main Information

Trade NameLipantil Supra 215 mg, film-coated tablet
Active SubstancesFenofibrate
Dosage FormFilm-coated tablet
Licence HolderMylan IRE Healthcare Limited
Licence NumberPA2010/015/004

Group Information

ATC CodeC10AB Fibrates
C10AB05 fenofibrate


License statusAuthorised
Licence Issued18/03/2005
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusNot marketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back